Prices are falling for the popular obesity treatments semaglutide (Wegovy) and tirzepatide (Zepbound), but steady access to the drugs remains challenging. The medications still amount to around $500 ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Tirzepatide could result in net lifetime health care costs of more than $16 trillion in the U.S. if all people eligible to ...

When we feed the body correctly, we can influence the same systems that drugs like Mounjaro target - helping regulate ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

Why is an increase of nearly 48% in India’s coastline relevant to the UPSC exam? What is the significance of topics such as ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7. ...

Dubbed the “King Kong” of weight loss jabs, Mounjaro, the brand name for tirzepatide, is a weekly injection licensed to treat type 2 diabetes on the NHS.

Tirzepatide is associated with longer continuous glycemic control than placebo or active comparators in type 2 diabetes (T2D). These findings, from a post hoc analysis, were published in Diabetes ...